Simponi Aria is used more for Rheumatoid Arthritis, compared to Psoriatic Arthritis and Ankylosing Spondylitis
Get Dexur’s Personalized Hospital Specific Presentation on Quality, Safety, Compliance & Education
By: Sruthy Iype Sep. 03, 2020
Dexur’s analysis of Medicare claims data showed that Simponi Aria was used more in the treatment of rheumatoid arthritis as compared to psoriatic arthritis and ankylosing spondylitis. The analysis was based on the J code (J1602) usage of the drug among Medicare patients who received outpatient care between Jan and Dec 2019. The analysis also looks at the average claims per patient data, which is a proxy for the number of injections / IV infusions / doses administered to a patient.
Simponi Aria (golimumab) is a biologic belonging to the drug class called tumor necrosis factor (TNF) blocker. The drug manufactured by Janssen Biotech is approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis. It targets TNF-alpha, a cytokine that regulates immunological responses and plays a key role in the pathogenesis of autoimmune disorders. By neutralising it, Simponi Aria helps to manage the symptoms of the disease, including inflammation and pain. This study examines the top diagnosis categories where the use of the drug has been observed.
| Diagnosis Category | Total Patients | Claims per Patient per year |
|---|---|---|
| Rheumatoid Arthritis | 4,024 | 4.1 |
| Psoriatic Arthritis | 750 | 3.8 |
| Ankylosing Spondylitis | 249 | 3.9 |
Simponi Aria’s use in the treatment of rheumatoid arthritis accounts for the largest proportion of its total usage. Between Jan and Dec 2019, the drug was administered to a total of 4,024 patients diagnosed with the autoimmune condition, wherein each patient had an average of 4.1 claims.
Psoriatic arthritis patients formed the second-largest diagnosis category associated with the use of Simponi Aria. During this period, 750 patients diagnosed with the condition received the drug as a part of their treatment. Psoriatic arthritis patients had an average of 3.8 claims per year for the drug.
Considerable usage of the drug was also seen in association with the treatment of ankylosing spondylitis. Simponi Aria was administered to 249 patients belonging to the diagnosis category over the 12-month period, each patient having 3.9 claims on an average for the drug.